- The company's Brazilian subsidiary is launching its third series of courses to teach doctors about cannabinoids, the endocannabinoid system and potential therapeutic uses of cannabidiol (CBD) in Brazil
- The seminar's educators include Dr. Junior S. Gibelli, HempMeds® Brasil Director of Medical Affairs; Gabriel Barbosa, Doctor in Biotechnology; and Dra. Ailane Araujo, Doctor in Functional Medicine and Integrative Nutrition
- Courses will be held at the HempMeds® Brasil headquarters in São Paulo on Monday, June 24, and Friday, June 28
SAN DIEGO, June 18, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® Brasil is hosting its third series of doctors' courses on cannabinoids and CBD at the HempMeds® Brasil headquarters in São Paulo on Monday, June 24, and Friday, June 28. The Company aims to host similar courses every month this year.
New Frontier Data's most recent report estimates that the Brazilian medical cannabis market could grow to $1.4 billion annually if CBD products are approved for additional uses.
"Many doctors in Brazil have started to show genuine interest in CBD and the work that we are doing here," said HempMeds® Brasil Vice President Caroline Heinz. "We hope to further develop our ongoing relationship with Brazilian healthcare professionals and provide them with the education and expertise they need to incorporate CBD into their practices."
The objectives of these courses are to train physicians of varied specialties about the potential possibilities of treatment involving cannabinoids in Brazil, simulate clinical studies and discuss principles of the endocannabinoid system. These courses will be taught by medical and scientific professionals including HempMeds® Brasil Director of Medical Affairs Dr. Junior S. Gibelli, Doctor in Biotechnology Gabriel Barbosa, and Dra. Ailane Araujo, Doctor in Functional Medicine and Integrative Nutrition.
"In order to continue as a global leader in cannabis education, we must host events like these to bring doctors together and discuss the benefits of CBD," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Regulatory bodies around the world are examining the safety and efficiency of CBD and doctors such as those who are attending our events can help push those conversations forward."
To learn more about these events, please visit https://hempmeds.com.br/.
About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the
National Sanitary Surveillance Agency (Anvisa) to import a product
based on cannabidiol, a substance derived from hemp, a plant of the
genus Cannabis. Currently, it is authorized to supply its
products, which help in the control of diseases such as epilepsy,
Parkinson's, chronic pain and multiple sclerosis, under medical
prescription. For these indications, the products can be
subsidized by the Brazilian government. HempMeds® Brasil works
on additional approvals for other indications. www.hempmeds.com.br.
About Medical Marijuana,
Inc.
We are a company of
firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with
three distinct business units in the non-psychoactive cannabinoid
space: a global portfolio of cannabinoid-based nutraceutical brands
led by Kannaway® and HempMeds®; a pioneer in sourcing the
highest-quality legal non-psychoactive cannabis products derived
from industrial hemp; and a cannabinoid-based clinical research and
botanical drug development sector led by its internal R&D and
scientific team and its pharmaceutical investment companies and
partners including AXIM® Biotechnologies, Inc. and
Kannalife, Inc. Medical Marijuana,
Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also
the first company to receive historic import permits for CBD
products from the governments of Brazil,
Mexico, Argentina, and
Paraguay and is a leader in the development of
international markets. Medical Marijuana, Inc.'s headquarters is in
San Diego, California, and additional information is
available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
FORWARD-LOOKING DISCLAIMER
This press
release may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward-looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of Medical Marijuana, Inc. to be materially different
from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA)
DISCLOSURE
These statements have not been evaluated by the
FDA and are not intended to diagnose, treat or cure any
disease.
LEGAL DISCLOSURE
Medical Marijuana,
Inc. does not sell or distribute any products that are in violation
of the United States Controlled Substances Act (US.CSA). These
companies do grow, sell, and distribute hemp-based products and are
involved with the federally legal distribution of medical
marijuana-based products within certain international markets.
Cannabidiol is a natural constituent of hemp oil.
CONTACT:
Public Relations
Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
[email protected]
www.cmwmedia.com
Investor Relations Contact:
P. (858) 283-4016
[email protected]
View original content:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-brasil-announces-third-series-of-cannabinoid-medicine-courses-in-sao-paulo-300870164.html